Literature DB >> 19107107

Treatment of infantile spasms in tuberous sclerosis complex: dismal outcomes but future hope?

Kevin C Ess1.   

Abstract

This commentary discusses a retrospective study by Muzykewicz et al. that details EEG results from children with infantile spasms in the setting of tuberous sclerosis complex (TSC). In this study, several factors were identified as being predictive of poor cognitive outcome, including worsening degree of hypsarrhythmia, abnormalities in EEG background activity, and incomplete response to vigabatrin. Notably, the majority of patients had a poor outcome, experiencing cognitive impairment and intractable epilepsy irrespective of whether they were treated with adrenocorticotropic hormone (corticotropin) or vigabatrin, despite the fact that vigabatrin has shown promise in previous studies. However, among the entire cohort a third of patients enjoyed greater than 1 year of seizure freedom and about a quarter had either mild or no cognitive impairment at follow-up. Overall, these findings underscore the great challenges that are faced in the treatment of infantile spasms in patients with TSC. I suggest that, while vigabatrin has been shown to have impressive short-term efficacy, the intractable seizures and cognitive impairment in many patients with TSC strongly indicate that new therapies and treatment strategies are urgently needed.

Entities:  

Year:  2008        PMID: 19107107     DOI: 10.1038/ncpneuro0994

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  7 in total

1.  Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG.

Authors:  David A Muzykewicz; Daniel J Costello; Elkan F Halpern; Elizabeth A Thiele
Journal:  Epilepsia       Date:  2008-09-17       Impact factor: 5.864

2.  Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.

Authors:  I Jambaqué; C Chiron; C Dumas; J Mumford; O Dulac
Journal:  Epilepsy Res       Date:  2000-02       Impact factor: 3.045

3.  Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.

Authors:  David Neal Franz; Jennifer Leonard; Cynthia Tudor; Gail Chuck; Marguerite Care; Gopalan Sethuraman; Argirios Dinopoulos; George Thomas; Kerry R Crone
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

4.  Randomized trial of vigabatrin in patients with infantile spasms.

Authors:  R D Elterman; W D Shields; K A Mansfield; J Nakagawa
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

5.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Lin Xu; David H Gutmann; Michael Wong
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

6.  Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.

Authors:  Susana E Camposano; Philippe Major; Elkan Halpern; Elizabeth A Thiele
Journal:  Epilepsia       Date:  2008-07       Impact factor: 5.864

7.  A retrospective study on aetiology based outcome of infantile spasms.

Authors:  Georges Karvelas; Anne Lortie; Morris H Scantlebury; Paul T Duy; Patrick Cossette; Lionel Carmant
Journal:  Seizure       Date:  2008-10-30       Impact factor: 3.184

  7 in total
  2 in total

1.  Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.

Authors:  Robert P Carson; Dominic L Van Nielen; Peggy A Winzenburger; Kevin C Ess
Journal:  Neurobiol Dis       Date:  2011-08-26       Impact factor: 5.996

2.  Safety and efficacy of vigabatrin for the treatment of infantile spasms.

Authors:  Michele A Faulkner; Justin A Tolman
Journal:  J Cent Nerv Syst Dis       Date:  2011-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.